PRKN and Parkinson disease: In the fourth study (Fig. 6a), we used an autosomal recessive PD mouse model (PARK2 mutation), characterized by metabolic dysregulation (Fig. 5a), mimicking some aspects of familiar PD to evaluate whether downregulation of CPT1 by a pharmacological blocker had any effect on behavior and pathological hallmarks of PD.